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.1. Need for developing case deﬁnitions and guidelines for data
ollection, analysis, and presentation for maternal death as an
dverse event following immunization
Every year, there are at least 200 million women who  become
regnant worldwide. Of these, approximately 585,000 women
ere reported to die each year as a result of pregnancy and
hildbirth related complications before the end of the second mil-
ennium by the WHO. More recent data suggest approximately a
fty percent decline in maternal deaths worldwide [1]. Although
hese statistics are encouraging, the death of a mother in itself is
 Disclaimer:  The ﬁndings, opinions and assertions contained in this consensus
ocument are those of the individual scientiﬁc professional members of the working
roup. They do not necessarily represent the ofﬁcial positions of each participant’s
rganization (e.g., government, university, or corporation). Speciﬁcally, the ﬁnd-
ngs  and conclusions in this paper are those of the authors and do not necessarily
epresent the views of their respective institutions.
∗ Corresponding author at: Department of Obstetrics and Gynecology, Wayne
tate University, 3990 John R, Detroit, MI  48201, USA. Tel.: +1 313 993 1388;
ax:  +1 313 966 4296.
E-mail address: contact@brightoncollaboration.org (M.  Patwardhan).
1 Brighton Collaboration homepage: http://www.brightoncollaboration.org.
ttp://dx.doi.org/10.1016/j.vaccine.2016.03.042
264-410X/© 2016 Published by Elsevier Ltd. This is an open access article under the CC Bcatastrophic and has a strong detrimental inﬂuence on not only the
newborn, but the entire family leading to a vast emotional, psy-
chosocial and economic vacuum. The exact number of women who
die each year secondary to pregnancy is still unknown, especially
since the majority of these events happen in remote rural areas
globally. There is a universal problem with underreporting and mis-
classiﬁcation of maternal deaths. In the USA, maternal death rate
from 1982 to 1996 was  actually 1.3 to 3 times the rate based solely
on vital statistics data [2].
It is important to establish pregnancy status, timing and cause
of death to deﬁne maternal death, but there exists considerable
variation in identifying symptoms, signs, diseases and methods of
deciphering and reporting cause of death. This in turn negatively
affects global coding of maternal deaths.
Considerable regional variations exist in the reporting of mater-
nal deaths [3]. Developing a universal deﬁnition for this major event
is crucial to prevent under reporting and to be able to assess global
data with consistency and accuracy in light of the United Nations
Millennium Development Goal (UN MDG) 5a that called for a 75%
reduction in the maternal mortality ratio between 1990 and 2015.
An expansion of the UN MDGs are Sustainable Development Goals
which are a new set of universal targets to enable international eco-
nomic, social and environmental development in the future. Within
the Sustainable Development Goals, the obstetrics and gynecol-
ogy community are urged to embrace opportunities and commit
Y license (http://creativecommons.org/licenses/by/4.0/).
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o playing a greater role in promoting the health of young couples
nd children in all countries and at all stages of economic devel-
pment. Reduction in maternal mortality is one of the integrated
ndicators of monitoring progress in this area [4,5]. Hence, aligning
he deﬁnition of maternal mortality is needed to enhance accurate
eporting and recording of progress.
.1.1. Vaccine considerations in pregnancy
Pregnancy is a state of generalized immune suppression geared
o decrease an antigen-speciﬁc response against the semi-allogenic
etus [6]. This altered autoimmunity also contributes to increase
n infectious disease severity e.g. pregnant women affected by
nﬂuenza suffer worse health outcomes than non-pregnant [7,8].
or maternal, fetal and neonatal protection, vaccination in preg-
ancy is encouraged and recommended. Live attenuated vaccines
ave not been utilized in pregnancy due to a theoretical possibil-
ty of infecting the fetus and the potential to cause an uncontrolled
ncrement in the vaccine virus load leading to severe or fatal reac-
ions. For this reason, inactivated vaccines are administered to
regnant women. But as with any drug or biological product, there
s a possibility of an adverse reaction or a side effect to the admin-
stered vaccine in pregnancy such as a severe allergic reaction
anaphylaxis) which is rare but may  be life-threatening.
An adverse reaction to a vaccine is deﬁned as an untoward effect
r any medical event caused by a vaccine that is extraneous to its
rimary purpose of producing immunity. It could be a true adverse
eaction or just a temporally coincidental event, which may  be
ndistinguishable from complications in pregnancy.
For the collection of adverse event following immunization
AEFI) information, the Brighton Collaboration Working Group
ecommends using AEFI report forms, following the existing
righton Collaboration guidelines as well as the data elements
s speciﬁed in the general drug safety guidelines by the Interna-
ional Conference on Harmonization of Technical Requirements
or Registration of Pharmaceuticals for Human Use (http://www.
ch.org), the ethical standards in research and reporting require-
ents for drug adverse events by the Council for International
rganizations of Medical Sciences (CIOMS, http://www.cioms.ch).
he Council for International Organizations of Medical Sciences
CIOMS) provides a case deﬁnition for a “Serious” AEFI as an
EFI that results in death, is life-threatening, requires in-patient
ospitalization or prolongation of existing hospitalization, results
n persistent or signiﬁcant disability/incapacity, or is a congen-
tal anomaly/birth defect (http://whqlibdoc.who.int/publications/
012/9789290360834 eng.pdf). Currently, there is no speciﬁc case
eﬁnition for “Maternal death following immunization”.
An AEFI can be causally attributed to vaccine more readily if it
ccurs during a plausible time period following vaccination and if
t corresponds to those previously associated with a particular vac-
ine [9,10]. For more than one reasons, the temporal association
f an AEFI may  be more complicated in pregnancy than otherwise.
or example, adverse events such as a mild inﬂammatory maternal
esponse [11] and chorioamnionitis [12] have been demonstrated
econdary to vaccination that have the potential to cause mater-
al morbidity and mortality. Also, a pregnant woman may  suffer
rom obstetric complications such as hemorrhage, hypertensive
isease of pregnancy, etc. that may  mimic  an AEFI. Thus a causative
ink to an adverse event may  be difﬁcult to establish. Also, care-
ul interpretation of its temporal association during pregnancy is
ssential. Due to superior antenatal surveillance and optimal med-
cal management available in some parts of the world now, a severe
cute maternal morbidity (SAMM)  or near-miss cases threatening
078 pregnant woman’s survival but not leading to her death, may
e averted in pregnancy for the time being. This may  temporarily
ncrease the rate of near-miss cases, but if complicated by death in
he future, may  be under reported as maternal deaths [13–17].e   
There are several studies that have tried to evaluate safety of
immunization in pregnancy. Maternal death following immuniza-
tion has not been reported in any of these. A review of reports to
the Vaccine Adverse event reporting system (VAERS) conducted
by the CDC did not report any maternal deaths from 1990 to
2009 after the administration of the inﬂuenza trivalent inactiv-
ated or the live attenuated vaccine. Similarly, no maternal deaths
were identiﬁed after immunization with Hepatitis A and B vaccine
[12], meningococcal polysaccharide protein conjugate vaccine [18],
tetanus toxide, reduced diptheria toxoid and acellular pertussis
vaccine [19].
According to the Tenth Revision of the International Classiﬁca-
tion of Diseases (ICD-10), a maternal death is the death of a woman
temporal to pregnancy, childbirth or the postpartum period, irre-
spective of the cause of death (including accidental or incidental
causes). Maternal deaths are further grouped based on the under-
lying cause of death such as direct and indirect causes and timing
of death such as late maternal deaths. Progress toward improve-
ment in maternal health status are measured by useful Maternal
Mortality indicators such as Maternal mortality rate and ratio.
Direct Maternal Death- direct maternal death is death of a
woman that results from obstetric complications of the pregnant
state, which includes pregnancy, labor, and puerperium. Direct
deaths can be caused by obstetric complications, unanticipated
complications arising due to interventions, omissions, incorrect
treatment, or from a chain of events resulting from a combina-
tion of these factors. WHO  estimates that the greatest proportion
of maternal deaths are due to direct causes which include hemor-
rhage (25%), sepsis (15%), abortion (13%), hypertensive disorders of
pregnancy (12%), and obstructed labor (8%).
Indirect Maternal Death – indirect maternal death is death
of a woman  caused by non-obstetric conditions or diseases that
may  exist before pregnancy, but is aggravated by the physiologic
effects of pregnancy. About 20% of maternal deaths are due to indi-
rect causes. Some examples of preexisting illnesses that may  be
aggravated by pregnancy are heart disease, iron deﬁciency anemia,
tuberculosis, hypertension, malaria, and diabetes mellitus.
Maternal death due to coincidental causes or other death –
maternal death due to coincidental causes or other death is death
during pregnancy, childbirth and the puerperium due to coinciden-
tal causes, e.g. suicide.
Maternal death due to unspeciﬁed causes – maternal death due
to unspeciﬁed causes is death during pregnancy, childbirth and the
puerperium where the underlying cause is unknown or was not
determined.
Late maternal death – late maternal death is death of a woman
from direct or indirect obstetric causes more than 42 days but less
than one year after termination of pregnancy.
Maternal mortality rate maternal mortality rate is the number
of maternal deaths per 1000 women of reproductive age (usually
15–49 years). This is an indicator of the risk of maternal death
among women of reproductive age and provides an indication of
the burden of maternal death in the adult female population.
Maternal mortality ratio maternal mortality ratio is the num-
ber of maternal deaths during a given time period per 100,000 live
births during the same time period. This is a more commonly used
indicator of risk of a woman of dying from a given pregnancy or her
obstetric risk.
1.2. Methods for the development of the case deﬁnition and
guidelines for data collection, analysis, and presentation for
maternal death as an adverse events following immunization
34 (2016) 6077–6083Following the process described in the overview paper [21]
as well as on the Brighton Collaboration Website http://www.
brightoncollaboration.org/internet/en/index/process.html, the
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 Vaccinrighton Collaboration Maternal death Working Group was  formed
n 2015 and included members of (clinical, academic, public health,
ndustry) background. The composition of the working and refer-
nce group as well as results of the web-based survey completed
y the reference group with subsequent discussions in the work-
ng group can be viewed at: http://www.brightoncollaboration.
rg/internet/en/index/working groups.html.
To guide the decision-making for the case deﬁnition and guide-
ines, a literature search was performed using Medline, PubMed and
he Cochrane Libraries, including the terms vaccines, vaccination,
r immunization and adverse pregnancy outcomes and/or maternal
eath. The search resulted in the identiﬁcation of 202 references.
ll abstracts were screened for possible reports of maternal death
ollowing immunization. Fifteen articles with potentially relevant
aterial were reviewed in more detail, in order to identify stud-
es using case deﬁnitions or, in their absence, providing clinical
escriptions of the case material. Multiple general medical text
ooks were also searched. Most publications were case reports of
ingle cases. The terminology was very inconsistent and no speciﬁc
eﬁnition for the adverse event was provided.
.3. Rationale for selected decisions about the case deﬁnition of
aternal death as an adverse event following immunization
According to the Tenth Revision of the International Classiﬁ-
ation of Diseases (ICD-10), a maternal death is the death of a
oman while pregnant or within 42 days of termination of preg-
ancy, irrespective of the duration and site of the pregnancy, from
ny cause related to or aggravated by the pregnancy or its man-
gement but not from accidental or incidental causes. Since death
ollowing immunization would likely be classiﬁed as an “inciden-
al cause”, it would not be reported as a “maternal death” and
ence would be under reported. Further to this, a maternal death
ollowing immunization may  not be recognized as such by the
ertiﬁer and has a signiﬁcant potential of being misclassiﬁed. To
void these problems of under reporting or misreporting, it is
ssential to formulate a terminology that follows the universal
eﬁnition of maternal mortality, is easily understood by the gen-
ral public while reporting and also encompasses all the missed
ases.
Using the broader ICD-10 terminology for recognizing mater-
al death as an adverse event following immunization, “Death of
 woman during pregnancy, childbirth and the puerperium that is
losely related temporally to an immunization event of the mother
hich is likely the single or contributory cause” may  be a more
ppropriate and pertinent deﬁnition.
.3.1. Timing post immunization
The incidence of anaphylactic or severe allergic reactions to
accines that have the potential to lead to death if unrecognized
nd untreated is reported to be extremely low with less than one
ase per million vaccine doses. More recent larger studies have not
eported any deaths in the general population. Signs and symptoms
rom vasovagal reactions are common after vaccination, espe-
ially in pregnancy, which can often be mistaken for anaphylactic
eactions [20]. Hence, correct diagnosis is important for accurate
eporting. Further to correct diagnosis is precision in determin-
ng speciﬁc time frames for onset of symptoms of adverse allergic
eactions following immunization [21–23].
The case deﬁnition is accompanied by guidelines which are
tructured according to the steps of conducting a clinical trial, i.e.
M.  Patwardhan et al. /ata collection, analysis and presentation. Neither case deﬁnition
or guidelines are intended to guide or establish criteria for man-
gement of ill infants, children, or adults. Both were developed to
mprove data comparability.1.4. Periodic review
Similar to all Brighton Collaboration case deﬁnitions and guide-
lines, review of the deﬁnition with its guidelines is planned on a
regular basis (i.e. every three to ﬁve years) or more often if needed.
2. Case deﬁnition of maternal death
Level 1
Diagnosis of pregnancy established by any of the following doc-
umented criteria:
a. Ultrasound examination
b. Fetal heart tones
c. Positive serum or urine human chorionic gonadotropin preg-
nancy test
d. Delivery of a neonate or other products of conception (abortus,
stillborn)
And
Death of the mother while pregnant or within 42 days of ter-
mination of pregnancy, irrespective of the duration and site of the
pregnancy
And
Documentation of Cause of death as:
. Direct: abortive outcome, hypertensive disorder, obstetric
hemorrhage, pregnancy related infection, other obstetric com-
plications, unanticipated complications
. Indirect: non obstetric complications
c. Death during pregnancy, childbirth and the puerperium: other
or coincidental
Level 2
Diagnosis of pregnancy established by any of the following crite-
ria in the absence of Level 1 criteria:
a. LMP  date
b. Serial Symphysio Fundal Height examinations
And
Death of the mother while pregnant or within 42 days of ter-
mination of pregnancy, irrespective of the duration and site of the
pregnancy
And
Documentation of Cause of death as:
a. Direct: abortive outcome, hypertensive disorder, obstetric
hemorrhage, pregnancy related infection, other obstetric com-
plications, unanticipated complications
b. Indirect: non-obstetric complications
c. Death during pregnancy, childbirth and the puerperium: other
or coincidental
d. Unspeciﬁed: unknown or undetermined
Level 3
Absence of Level 1 or 2 criteria for establishing diagnosis of
pregnancy and:
a. Unsure LMP
b. No clinical examination documented
e   34 (2016) 6077–6083 6079And
Death of the mother temporal to pregnancy, childbirth or the
postpartum period when exact timing of death is unknown
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(15) For all cases at any level of diagnostic certainty and for
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And
Documentation of cause of death as:
a. Direct: abortive outcome, hypertensive disorder, obstetric
hemorrhage, pregnancy related infection, other obstetric com-
plications, unanticipated complications
. Indirect: non obstetric complications
c. Death during pregnancy, childbirth and the puerperium: other
or coincidental
. Unspeciﬁed: unknown or undetermined.
. Guidelines for data collection, analysis and presentation
f maternal death
It was the consensus of the Brighton Collaboration Maternal
eath Working Group to recommend the following guidelines
o enable meaningful and standardized collection, analysis, and
resentation of information about maternal death. However,
mplementation of all guidelines might not be possible in all sett-
ngs. The availability of information may  vary depending upon
esources, geographical region, and whether the source of infor-
ation is a prospective clinical trial, a post-marketing surveillance
r epidemiological study, or an individual report of maternal
eath. Also, as explained in more detail in the overview paper
n this volume, these guidelines have been developed by this
orking group for guidance only, and are not to be consid-
red a mandatory requirement for data collection, analysis, or
resentation.
.1. Data collection
These guidelines represent a desirable standard for the collec-
ion of data on availability following immunization to allow for
omparability of data, and are recommended as an addition to data
ollected for the speciﬁc study question and setting. The guidelines
re not intended to guide the primary reporting of maternal death
o a surveillance system or study monitor. Investigators develop-
ng a data collection tool based on these data collection guidelines
lso need to refer to the criteria in the case deﬁnition, which are not
epeated in these guidelines. The Brighton Collaboration has devel-
ped guidelines for data collection https://brightoncollaboration.
rg/public/resources/standards/guidelines.html; and data col-
ection forms https://brightoncollaboration.org/public/resources/
ata-collection-forms.html.
Guidelines 1–40 below have been developed to address data ele-
ents for the collection of adverse event information as speciﬁed
n general drug safety guidelines by the International Confer-
nce on Harmonization of Technical Requirements for Registration
f Pharmaceuticals for Human Use (International Conference
n Harmonisation of Technical Requirements for Registration of
harmaceuticals for Human Use (ICH) (24), and the form for
eporting of drug adverse events by the Council for International
rganizations of Medical Sciences (Council for International Orga-
izations of Medical Sciences (CIOMS) (25). These data elements
nclude an identiﬁable reporter and patient, one or more prior
mmunisations, and a detailed description of the adverse event, in
his case, of maternal death following immunization. The additional
uidelines have been developed as guidance for the collection of
M.  Patwardhan et al. /080dditional information to allow for a more comprehensive under-
tanding of maternal death following immunization.
.1.1. Source of information/reporter
For all cases and/or all study participants, as appropriate, the
ollowing information should be recorded:(1) Date of report.
(2) Name and contact information of person reporting2 and/or
diagnosing maternal death as speciﬁed by country-speciﬁc data
protection law.
(3) Name and contact information of the investigator responsible
for the subject, as applicable.
(4) Relation to the patient (e.g., immunizer [clinician, nurse], family
member [indicate relationship], other).
3.1.2. Vaccinee/control
3.1.2.1. Demographics. For all cases and/or all study participants,
as appropriate, the following information should be recorded:
(5) Case/study participant identiﬁers (e.g. ﬁrst name initial fol-
lowed by last name initial) or code (or in accordance with
country-speciﬁc data protection laws).
(6) Date of birth, age, sex, ethnicity.
3.1.2.2. Clinical and immunization history. For all cases and/or
all study participants, as appropriate, the following information
should be recorded:
(7) Past medical history, including hospitalizations, underlying
diseases/disorders, pre-immunization signs and symptoms
including identiﬁcation of indicators for, or the absence of, a his-
tory of allergy to vaccines, vaccine components or medications;
food allergy; allergic rhinitis; eczema; asthma.
(8) Any medication history (other than treatment for the event
described) prior to, during, and after immunization including
prescription and non-prescription medication as well as med-
ication or treatment with long half-life or long term effect
(e.g. immunoglobulins, blood transfusion and immunosup-
pressants).
(9) Immunization history (i.e. previous immunizations and any
adverse event following immunization (AEFI)).
3.1.3. Details of the immunization
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(10) Date and time of immunization(s) and timing of immunization
in relation with pregnancy: antepartum, intrapartum, or post-
partum {antepartum: day or week of pregnancy or trimester,
ascertainment method for time of conception (LMP, fundal
height, ultrasound); postpartum: day or week postpartum}.
(11) Description of vaccine(s) (name of vaccine, manufacturer, lot
number, dose (e.g. 0.25 mL,  0.5 mL,  etc.) composition of any
diluent administered separately or added to the vaccine, and
number of dose if part of a series of immunisations against the
same disease).
(12) The anatomical sites (including left or right side) of all immu-
nisations (e.g. vaccine A in proximal left lateral thigh, vaccine
B in left deltoid).
(13) Route and method of administration (e.g. intramuscular, intra-
dermal, subcutaneous, and needle-free (including type and
size), other injection devices).
(14) Needle length and gauge.
3.1.4. The adverse event
ne   34 (2016) 6077–6083reported events with insufﬁcient evidence, the criteria ful-
ﬁlled to meet the case deﬁnition should be recorded.
2 If the reporting center is different from the vaccinating center, appropriate and
timely communication of the adverse event should occur.
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(a) The issuer of death certiﬁcate (physician or other person
authorized by the local law to issue death certiﬁcate) if a death
certiﬁcate was issued,
(b) Place of death (hospital, health facility other than hospital, in
transportation, home)
(c) If an autopsy was performed with results
(d) If a verbal autopsy was performed with results
(e) Cause of death as
i. Direct: abortive outcome, hypertensive disorder, obstetric
hemorrhage, pregnancy related infection, other obstetric
complications, unanticipated complications
ii. Indirect: non obstetric complications
iii. Death during pregnancy, childbirth and the puerperium: other
or coincidental
iv. Unspeciﬁed: unknown or undetermined
16) Clinical description of signs and symptoms preceding mater-
nal death, and if there was medical conﬁrmation of the event
(i.e. patient seen by physician).
17) Date/time of onset,3 diagnosis,4 clinical events5 and ﬁnal
outcome.6
18) Concurrent signs, symptoms, and diseases.
19) Measurement/testing
• Values and units of routinely measured parameters (e.g. tem-
perature, blood pressure) – in particular those preceding
maternal death;
• Method of measurement (e.g. type of thermometer, oral or
other route, duration of measurement, etc.);
• Results of laboratory examinations, surgical and/or patholog-
ical ﬁndings and diagnoses if present.
20) Objective clinical evidence supporting classiﬁcation of the
event.7
21) Exposures other than the immunization 24 h before and after
immunization (e.g. food, environmental) considered poten-
tially relevant to the reported event.
.1.5. Miscellaneous/general
22) The duration of surveillance for maternal death should be pre-
deﬁned based on
• Biologic characteristics of the vaccine e.g. live attenuated
versus inactivated component vaccines;
M.  Patwardhan et al. /• Biologic characteristics of the vaccine-targeted disease;
• Biologic characteristics of maternal death including patterns
identiﬁed in previous trials (e.g. early-phase trials); and
3 The date and/or time of onset is deﬁned as the time post immunization, when
he ﬁrst sign or symptoms preceding maternal death occurred. This may only be
ossible to determine in retrospect.
4 The date of diagnosis of an episode is the day post immunization when the event
et  the case deﬁnition at any level.
5 E.g. Clinical events preceding maternal death, therapeutic interventions needed.
6 An AEFI is deﬁned as serious by international standards if it meets one or
ore of the following criteria: (1) it results in death, (2) is life-threatening, (3) it
equires inpatient hospitalization or results in prolongation of existing hospitaliza-
ion, (4) results in persistent or signiﬁcant disability/incapacity, (5) is a congenital
nomaly/birth defect, (6) is a medically important event or reaction.
7 To determine the appropriate category, the user should ﬁrst establish, whether
 reported event meets the criteria for the lowest applicable level of diagnostic
ertainty, e.g. Level three. If the lowest applicable level of diagnostic certainty of
he  deﬁnition is met, and there is evidence that the criteria of the next higher level
f  diagnostic certainty are met, the event should be classiﬁed in the next category.
his approach should be continued until the highest level of diagnostic certainty
or a given event could be determined. Major criteria can be used to satisfy the
equirement of minor criteria. If the lowest level of the case deﬁnition is not met, it
hould be ruled out that any of the higher levels of diagnostic certainty are met  and
he event should be classiﬁed in additional categories four or ﬁve.• Biologic characteristics of the vaccinee (e.g. nutrition, under-
lying disease like immunosuppressive illness).
(23) The duration of follow-up reported during the surveillance
period should be predeﬁned likewise. It should aim to con-
tinue to resolution of the event.
(24) Methods of data collection should be consistent within and
between study groups, if applicable.
(25) Follow-up of cases should attempt to verify and complete the
information collected as outlined in data collection guidelines
1–24.
(26) Investigators of patients with maternal death should provide
guidance to reporters to optimize the quality and complete-
ness of information provided.
(27) Reports of maternal death should be collected throughout the
study period regardless of the time elapsed between immu-
nization and the adverse event. If this is not feasible due to the
study design, the study periods during which safety data are
being collected should be clearly deﬁned.
3.2. Data analysis
The following guidelines represent a desirable standard for anal-
ysis of data on maternal death to allow for comparability of data,
and are recommended as an addition to data analyzed for the spe-
ciﬁc study question and setting.
(28) Reported events should be classiﬁed in one of the following
ﬁve categories including the three levels of diagnostic cer-
tainty. Events that meet the case deﬁnition should be classiﬁed
according to the levels of diagnostic certainty as speciﬁed in
the case deﬁnition. Events that do not meet the case deﬁnition
should be classiﬁed in the additional categories for analysis.
Event classiﬁcation in 5 categories66
Event meets case deﬁnition
(1) Level 1: Criteria as speciﬁed in the Maternal death case deﬁni-
tion
(2) Level 2: Criteria as speciﬁed in the Maternal death case deﬁni-
tion
(3) Level 3: Criteria as speciﬁed in the Maternal death case deﬁni-
tion
Event does not meet case deﬁnition
Additional categories for analysis
(4) Reported maternal death with insufﬁcient evidence to meet the
case deﬁnition8
(5) Not a case of maternal death9
(29) The interval between immunization and reported maternal
death could be deﬁned as the date/time of immunization to
the date/time of maternal death. If few cases are reported,
the concrete time course could be analyzed for each; for a
large number of cases, data can be analyzed in the following
e   34 (2016) 6077–6083 6081increments: see Table 1.
(30) The duration of events leading to maternal death could be ana-
lyzed as the interval between the date/time of onset11 of the
ﬁrst symptoms and/or signs consistent with the deﬁnition and
8 If the evidence available for an event is insufﬁcient because information is
missing, such an event should be categorized as “Reported death with insufﬁcient
evidence to meet the case deﬁnition”.
9 An event does not meet the case deﬁnition if investigation reveals a negative
ﬁnding of a necessary criterion (necessary condition) for diagnosis. Such an event
should be rejected and classiﬁed as “Not a case of maternal death”.
 Table  1
Subjects with maternal death by interval to presentation.a
Interval Day or week of pregnancy
(trimester or postpartum)
Number Percentage
0–72 h after immunization
More than 72 h to 7 days after immunization
More than 7 days to 30 days after immunization
More than 30 days after immunization
Time unit increments thereafter
Total
ays of
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the online version, at http://dx.doi.org/10.1016/j.vaccine.2016.03.
042.
M.  Patwardhan et al. / Vaccine   34 (2016) 6077–60836082a Presentation should include death of the mother while pregnant or within 42 d
eath  of the mother temporal to pregnancy, childbirth or the postpartum period w
the ﬁnal outcome.55 Whatever start and ending are used, they
should be used consistently within and across study groups.
31) If more than one measurement of a particular criterion is taken
and recorded, the value corresponding to the greatest magni-
tude of the adverse experience could be used as the basis for
analysis. Analysis may  also include other characteristics like
qualitative patterns of criteria deﬁning the event.
32) The distribution of data (as numerator and denominator data)
could be analyzed in predeﬁned increments (e.g. measured
values, times), where applicable. Increments speciﬁed above
should be used. When only a small number of cases are pre-
sented, the respective values or time course can be presented
individually.
33) Data on maternal death obtained from subjects receiving a
vaccine should be compared with those obtained from an
appropriately selected and documented control group(s) to
assess background rates of maternal death in non-exposed
populations, and should be analyzed by study arm and dose
where possible, e.g. in prospective clinical trials.
.3. Data presentation
These guidelines represent a desirable standard for the pre-
entation and publication of data on maternal death following
mmunization to allow for comparability of data, and are recom-
ended as an addition to data presented for the speciﬁc study
uestion and setting. Additionally, it is recommended to refer
o existing general guidelines for the presentation and publi-
ation of randomized controlled trials, systematic reviews, and
eta-analyses of observational studies in epidemiology (e.g. state-
ents of Consolidated Standards of Reporting Trials (CONSORT),
f Improving the quality of reports of meta-analyses of ran-
omized controlled trials (QUORUM), and of Meta-analysis Of
bservational Studies in Epidemiology (MOOSE), respectively)
26–28).
34) All reported events of maternal death should be presented
according to the categories listed in guideline 29.
35) Data on possible maternal death events should be presented
in accordance with data collection guidelines 1–27 and data
analysis guidelines 28–33
36) Data should be presented with numerator and denominator
(n/N) (and not only in percentages), if available.
Although immunization safety surveillance systems
denominator data are usually not readily available, attempts
should be made to identify approximate denominators. The
source of the denominator data should be reported and
calculations of estimates be described (e.g. manufacturer data
like total doses distributed, reporting through Ministry of
Health, coverage/population based data, etc.).
37) The incidence of cases in the study population should be pre-
sented and clearly identiﬁed as such in the text. termination of pregnancy, irrespective of the duration and site of the pregnancy or
act timing of death is unknown.
(38) If the distribution of data is skewed, median and inter-quartile
range (IQR) with mention of both the ﬁrst and third quar-
tiles (Q1 and Q3) are usually the more appropriate statistical
descriptors than a mean. However, the mean and standard
deviation should also be provided.
(39) Any publication of data on maternal death should include a
detailed description of the methods used for data collection
and analysis as possible. It is essential to specify:
• The study design;
• The method, frequency and duration of monitoring for mater-
nal death;
• The trial proﬁle, indicating participant ﬂow during a study
including drop-outs and withdrawals to indicate the size and
nature of the respective groups under investigation;
• The type of surveillance (e.g. passive or active surveillance);
• The characteristics of the surveillance system (e.g. population
served, mode of report solicitation);
• The search strategy in surveillance databases;
• Comparison group(s), if used for analysis;
• The instrument of data collection (e.g. standardized question-
naire, diary card, report form);
• Whether the day of immunization was  considered “day one”
or “day zero” in the analysis;
• Whether the date of onset22 and/or the date of diagnosis33
or date of registration/documentation/reporting was used for
analysis
• Use of this case deﬁnition for maternal death, in the abstract
or methods section of a publication10
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